Cristiana Sessa
A5086081284- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Endometrial and Cervical Cancer Treatments
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- PARP inhibition in cancer therapy
- Chemotherapy-induced organ toxicity mitigation
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-induced cardiotoxicity and mitigation
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Metal complexes synthesis and properties
- Chemotherapy-related skin toxicity
- Angiogenesis and VEGF in Cancer
- Cancer Mechanisms and Therapy
- Lymphoma Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
Università della Svizzera italiana
2005-2024
Institute of Oncology Research
2014-2024
Ente Ospedaliero Cantonale
2018-2024
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2024
European School of Oncology
2024
Ospedale Regionale di Bellinzona e Valli
2012-2023
Swiss Group For Clinical Cancer Research
2010-2023
Novartis (Switzerland)
2009-2023
Princess Margaret Cancer Centre
2021-2023
Universitat Autònoma de Barcelona
2010-2023
<h3>Abstract</h3> The first joint European Society for Medical Oncology (ESMO), SocieTy Radiotherapy & (ESTRO) and of Gynaecological (ESGO) consensus conference on endometrial cancer was held 11–13 December 2014 in Milan, Italy, comprised a multidisciplinary panel 40 leading experts the management cancer. Before conference, expert prepared three clinically-relevant questions about relating to following four areas: prevention screening, surgery, adjuvant treatment advanced recurrent...
PURPOSE: To determine the side effects and feasibility of cisplatin carboplatin each in combination with paclitaxel as front-line therapy advanced epithelial ovarian cancer. PATIENTS AND METHODS: Patients were randomly allocated to receive 175 mg/m 2 intravenously a 3-hour infusion followed by either 75 or (area under plasma concentration-time curve 5), both on day 1. The schedule was repeated every 3 weeks for at least six cycles. Women paclitaxel-cisplatin admitted hospital, whereas...
MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, pharmacokinetics of buparlisib (pan class PI3K inhibitor) trametinib (MEK were evaluated.This open-label, dose-finding, phase Ib study comprised dose escalation, followed by expansion part patients with RAS- or BRAF-mutant non-small cell lung, ovarian, pancreatic cancer.Of note, 113 enrolled, 66 47 dose-escalation -expansion parts, respectively. MTD was established as 70 mg + 1.5...
The European Society of Gynaecological Oncology, the for Medical Oncology (ESMO) and Pathology held a consensus conference (CC) on ovarian cancer 15-16 June 2022 in Valencia, Spain. CC panel included 44 experts management pathology, an ESMO scientific advisor methodologist. aim was to discuss new or contentious topics develop recommendations improve harmonise patients with cancer. Eighteen questions were identified discussion under four main topics: (i) pathology molecular biology, (ii)...
The first joint European Society for Medical Oncology (ESMO), SocieTy Radiotherapy & (ESTRO) and of Gynaecological (ESGO) consensus conference on endometrial cancer was held 11–13 December 2014 in Milan, Italy, comprised a multidisciplinary panel 40 leading experts the management cancer. Before conference, expert prepared three clinically-relevant questions about relating to following four areas: Prevention screening, surgery, adjuvant treatment advanced recurrent disease. All relevant...
A phase I study was conducted with the primary objective of determining maximum tolerated dose (MTD) AUY922 in patients advanced solid tumors. Secondary objectives included characterization safety, pharmacokinetic, and pharmacodynamic profiles.Patients tumors received 1-hour i.v. infusions once a week 28-day cycle. An adaptive Bayesian logistic regression model that employed observed dose-limiting toxicities (DLT) first treatment cycle used to guide dose-escalation decisions, established MTD...
The surgical management of advanced ovarian cancer involves complex surgery. Implementation a quality program has major impact on survival. goal this work was to develop list indicators (QIs) for surgery that can be used audit and improve the clinical practice. This task been carried out under auspices European Society Gynaecologic Oncology (ESGO).Quality were based scientific evidence and/or expert consensus. A 4-step evaluation process included systematic literature search identification...
This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of mammalian target rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. Women measurable recurrent or persistent cancer documented disease progression were treated 12.5 mg intravenously once daily for 5 consecutive days every weeks a 4-week cycle. The primary end point was clinical benefit response, defined as an objective response prolonged stable 16 more. In all, 45 patients...
Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This study evaluated olaparib capsules combination liposomal doxorubicin (PLD) advanced solid tumours (NCT00819221). Patients received 28-day cycles of olaparib, continuously (days 1–28) or intermittently 1–7), plus PLD (40 mg m−2, day 1); seven dose cohorts (50–400 bid) were explored to determine the recommended dose. Assessments...